The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells

Gynecologic Oncology

Volumn 137, Issue 1, 2015, Pages 143-151

  Pink, Ryan Charles ^a   Samuel, Priya ^a   Massa, Davide ^a   Caley, Daniel Paul ^a,b   Brooks, Susan Ann ^a   Carter, David Raul Francisco ^a  

^a OXFORD BROOKES UNIVERSITY   (United Kingdom)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cisplatin; Exosome; miRNA; Ovarian cancer; Resistance

Indexed keywords

CARBOPLATIN; CISPLATIN; MESSENGER RNA; MICRORNA; MICRORNA 132; MICRORNA 21 3P; MICRORNA 222; MICRORNA 27B; MICRORNA 29B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; MIRN21 MICRORNA, HUMAN; NAV3 PROTEIN, HUMAN; NERVE PROTEIN;

ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; EXOSOME; FEMALE; GENE PRODUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; LUCIFERASE ASSAY; MICROARRAY ANALYSIS; MTT ASSAY; OVARIAN CANCER CELL LINE; OVARY CANCER; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTOMICS; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENE SILENCING; GENETICS; METABOLISM; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEMBRANE PROTEINS; MICRORNAS; NERVE TISSUE PROTEINS; OVARIAN NEOPLASMS;

EID: 84929939631     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.12.042     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Aletti G, Gallenberg M, ClibyW, Jatoi A, Hartmann L. Currentmanagement strategies for ovarian cancer. Mayo Clin Proc 2007;82:751-70.
4. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987;34:155-66.
5. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31:1869-83.
6. Caley DP, Pink RC, Trujillano D, Carter DR. Long noncoding RNAs, chromatin, and development. ScientificWorldJournal 2010;10:90-102.
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136: 215-33.
8. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466:835-40.
9. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007;318:1931-4.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97.
11. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6:376-85.
12. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115:199-208.
13. Suzuki HI, Miyazono K. Emerging complexity of microRNA generation cascades. J Biochem 2011;149:15-25.
14. Jacobs LA, Bewicke-Copley F, PoolmanMG, Pink RC, Mulcahy LA, Baker I, et al. Metaanalysis using a novel database, miRStress, reveals miRNAs that are frequently associated with the radiation and hypoxia stress-responses. PLoS One 2013;8:e80844.
15. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One 2012;7: e34546.
16. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15.
17. Al-Mayah AH, Irons SL, Pink RC, Carter DR, Kadhim MA. Possible role of exosomes containing RNA in mediating nontargeted effect of ionizing radiation. Radiat Res 2012;177(5):539-45.
18. Chen WX, Liu XM, Lv MM, Chen L, Zhao JH, Zhong SL, et al. Exosomes from drugresistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One 2014;9:e95240.
19. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009;113:249-55.
20. Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai Y, et al. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci 2011;124:359-68.
21. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010;42:1282-90.
22. Ziliak D, Gamazon ER, Lacroix B, Kyung Im H, Wen Y, Huang RS. Genetic variation that predicts platinum sensitivity reveals the role ofmiR-193b∗ in chemotherapeutic susceptibility. Mol Cancer Ther 2012;11:2054-61.
23. Pors K, Plumb JA, Brown R, Teesdale-Spittle P, Searcey M, Smith PJ, et al. Development of nonsymmetrical 1, 4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells. J Med Chem 2005;48:6690-5.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
25. Patnaik SK, Dahlgaard J, MazinW, Kannisto E, Jensen T, Knudsen S, et al. Expression of microRNAs in the NCI-60 cancer cell-lines. PLoS One 2012;7:e49918.
26. Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, et al. Docetaxelresistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 2012;7:e50999.
27. Karenko L, Hahtola S, Päivinen S, Karhu R, Syrjä S, Kähkönen M, et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res 2005;65:8101-10.
28. Carlsson E, Ranki A, Sipilä L, Karenko L, Abdel-RahmanWM, Ovaska K, et al. Potential role of a navigator gene NAV3 in colorectal cancer. Br J Cancer 2012;106:517-24.
29. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011;44:839-47.
30. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006;126:1203-17.
31. Antonov AV, Knight RA, Melino G, Barlev NA, Tsvetkov PO. MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets. Cell Death Differ 2013;20:367.
32. Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2011;2:1265-78.
33. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, et al. Systematic bioinformatic analysis of expression levels of 17, 330 human genes across 9, 783 samples from 175 types of healthy and pathological tissues. Genome Biol 2008;9:R139.
34. Peters D, Freund J, Ochs RL. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 2005;4:1605-16.
35. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36.
36. Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2010;10:1224-32.
37. Yang SM, Huang C, Li XF, Yu MZ, He Y, Li J. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 2013;306:162-8.
38. Liu ZL, Wang H, Liu J, Wang ZX. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 2013;372:35-45.
39. Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT, Zhang CP. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010;46:317-22.
40. Mah SM, Buske C, Humphries RK, Kuchenbauer F. miRNA∗: a passenger stranded in RNA-induced silencing complex? Crit Rev Eukaryot Gene Expr 2010;20:141-8.
41. van Haren J, Draegestein K, Keijzer N, Abrahams JP, Grosveld F, Peeters PJ, et al. Mammalian Navigators are microtubule plus-end tracking proteins that can reorganize the cytoskeleton to induce neurite-like extensions. Cell Motil Cytoskeleton 2009;66:824-38.
42. Carlsson E, Krohn K, Ovaska K, Lindberg P, Häyry V, Maliniemi P, et al. Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis. Genes Chromosomes Cancer 2013;52:191-201.
43. Ranki A, Väkevä L, Sipilä L, Krohn K. Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma. Acta Derm Venereol 2011;91:568-73.
44. Challagundla KB, Fanini F, Vannini I, Wise P, Murtadha M, Malinconico L, et al. microRNAs in the tumormicroenvironment: solving the riddle for a better diagnostics. Expert Rev Mol Diagn 2014;14:565-74.
45. Zhang FF, Zhu YF, Zhao QN, Yang DT, Dong YP, Jiang L, et al. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance. Eur J Pharmacol 2014;738:83-90.